Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 18/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PTPRA | P18433 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064346 | 0.78 | PTPN1 (0.62) | PTPN1 | |
| SCHEMBL7065042 | 0.77 | PTPN1 (0.64) | PTPN1 | |
| SCHEMBL1239567 | 0.76 | PTPN1 (0.59) | PTPN1PTPRA | |
| SCHEMBL7060842 | 0.75 | PTPN1 (0.49) | PTPN1LMNAKMT2AKDM4EALDH1A1 | |
| SCHEMBL7062370 | 0.75 | PTPN1 (0.55) | PTPN1LMNAPTPRA | |
| SCHEMBL2092277 | 0.74 | NPC1 (0.43) | MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL7065662 | 0.73 | PTPN1 (0.59) | PTPN1MEN1LMNAKMT2AKDM4E | |
| SCHEMBL2092273 | 0.73 | GPBAR1 (0.41) | MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL7062441 | 0.71 | PTPN1 (0.54) | PTPN1MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL7064433 | 0.69 | PTPN1 (0.65) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | claimed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | claimed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | claimed |
| EP-4154908-A1 | COMPOSITIONS AND METHODS FOR TREATING, INCLUDING PREVENTING, PARVOVIRUS INFECTIONS AND RELATED DISEASES | University Of Louisville Research Foundation, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20210292372-A1 | COMPOSITIONS AND METHODS FOR TREATING, INCLUDING PREVENTING, PARVOVIRUS INFECTIONS AND RELATED DISEASES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11008367-B2 | Compositions and methods for treating, including preventing, parvovirus infections and related diseases | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| CN-110845581-A | Compositions and methods for treating (including preventing) parvovirus infection and related diseases | 路易斯维尔大学研究基金会有限公司 | 2020-02-28 | — | — | CN | disclosed |
| CN-106456742-B | Compositions and methods for treating (including preventing) parvovirus infection and related diseases | 路易斯维尔大学研究基金会有限公司 | 2020-02-04 | — | — | CN | disclosed |
| US-20190202867-A1 | COMPOSITIONS AND METHODS FOR TREATING, INCLUDING PREVENTING, PARVOVIRUS INFECTIONS AND RELATED DISEASES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-20170015712-A1 | COMPOSITIONS AND METHODS FOR TREATING, INCLUDING PREVENTING, PARVOVIRUS INFECTIONS AND RELATED DISEASES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| EP-3116540-A1 | COMPOSITIONS AND METHODS FOR TREATING, INCLUDING PREVENTING, PARVOVIRUS INFECTIONS AND RELATED DISEASES | University Of Louisville Research Foundation, Inc. (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015138424-A1 | COMPOSITIONS AND METHODS FOR TREATING, INCLUDING PREVENTING, PARVOVIRUS INFECTIONS AND RELATED DISEASES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATON, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002079410-A2 | GLUCAN CHAIN LENGTH DOMAINS | BASF PLANT SCIENCE GMBH (DE) | 2002-10-10 | — | — | WO | disclosed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | disclosed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| CN-1323345-A | A modified polypeptide with reduced immune response | NOVO JYMES AS (DK) | 2001-11-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | PPM1A, PTPRO, PTP4A1 | PTPN1 10/4885MEN1 3065/4885LMNA 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.